An allosteric modulator of metabotropic glutamate receptors (mGluR 2), (+)-TFMPIP, inhibits restraint stress-induced phasic glutamate release in rat prefrontal cortex

Journal of Neurochemistry

Volumn 122, Issue 3, 2012, Pages 619-627

  Hascup, Erin R ^a   Hascup, Kevin N ^a   Pomerleau, Francois ^b   Huettl, Peter ^b   Hajos Korcsok, Eva ^c   Kehr, Jan ^a   Gerhardt, Greg A ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF KENTUCKY   (United States)

^c PFIZER INC   (United States)

Author keywords

amperometry; anxiolytic; biosensor; mood disorder; neurotransmitter; therapeutic targets

Indexed keywords

EGLUMETAD; GLUTAMIC ACID; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR AGONIST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; DRUG DETERMINATION; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME RELEASE; MALE; NERVE CELL; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; STRESS;

ALLOSTERIC REGULATION; ANIMALS; BICYCLO COMPOUNDS; BICYCLO COMPOUNDS, HETEROCYCLIC; BODY WEIGHT; EXCITATORY AMINO ACID AGONISTS; GLUTAMIC ACID; MALE; MICROELECTRODES; PIPERIDINES; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; RESTRAINT, PHYSICAL; WAKEFULNESS;

RATTUS;

EID: 84863725424     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2012.07784.x     Document Type: Article

References (48)

1. Bagley J., and, Moghaddam B., (1997) Temporal dynamics of glutamate efflux in the prefrontal cortex and in the hippocampus following repeated stress: effects of pretreatment with saline or diazepam. Neuroscience 77, 65-73.
2. Bonnefous C., Vernier J. M., Hutchinson J. H., Gardner M. F., Cramer M., James J. K., et al. (2005) Biphenyl-indanones: allosteric potentiators of the metabotropic glutamate subtype 2 receptor. Bioorg. Med. Chem. Lett. 15, 4354-4358.
3. Burmeister J. J., and, Gerhardt G. A., (2001) Self-referencing ceramic-based multisite microelectrodes for the detection and elimination of interferences from the measurement of L-glutamate and other analytes. Anal. Chem. 73, 1037-1042.
4. Burmeister J. J., Moxon K., and, Gerhardt G. A., (2000) Ceramic-based multisite microelectrodes for electrochemical recordings. Anal. Chem. 72, 187-192.
5. Burmeister J. J., Pomerleau F., Palmer M., Day B. K., Huettl P., and, Gerhardt G. A., (2002) Improved ceramic-based multisite microelectrode for rapid measurements of L-glutamate in the CNS. J. Neurosci. Methods 119, 163-171.
6. Burmeister J. J., Coates T. D., and, Gerhardt G. A., (2004) Multisite microelectrode arrays for measurements of multiple neurochemicals. Conf Proc IEEE Eng. Med. Biol. Soc. 7, 5348-5351.
7. Danbolt N. C., (2001) Glutamate uptake. Prog. Neurobiol. 65, 1-105.
8. Dunayevich E., Erickson J., Levine L., Landbloom R., Schoepp D. D., and, Tollefson G. D., (2008) Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology 33, 1603-1610.
9. Estanislau C., Ramos A. C., Ferraresi P. D., Costa N. F., de Carvalho H. M., and, Batistela S., (2011) Individual differences in the elevated plus-maze and the forced swim test. Behav. Processes 86, 46-51.
10. Fell M. J., Witkin J. M., Falcone J. F., et al. (2011) N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl) -1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes. J. Pharmacol. Exp. Ther. 336, 165-177.
11. Figueiredo H. F., Bruestle A., Bodie B., Dolgas C. M., and, Herman JP, (2003) The medial prefrontal cortex differentially regulates stress-induced c-fos expression in the forebrain depending on type of stressor. Eur. J. Neurosci. 18, 2357-2364.
12. de la Fuente-Sandoval C., Leon-Ortiz P., Favila R., Stephano S., Mamo D., and, Ramirez-Bermudez J,., et al. (2011). Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology 36, 1781-1791.
13. Graeff F. G., Netto C. F., and, Zangrossi Jr H., (1998) The elevated T-maze as an experimental model of anxiety. Neurosci. Biobehav. Rev. 23, 237-246.
14. Hascup K. N, Rutherford E. C., Quintero J. E., Day B. K., Nickell J., Pomerleau F., et al. (2006) Second-by-second measures of l-glutamate and other neurotransmitters using enzyme-based microelectrode arrays, in Electrochemical Methods for Neuroscience (, Michael A. C., and, Borland L. M., eds.), pp. 407-450. CRC Press, Boca Raton.
15. Hascup K. N., Hascup E. R., Pomerleau F., Huettl P., and, Gerhardt G. A., (2008) Second-by-second measures of L-glutamate in the prefrontal cortex and striatum of freely moving mice. J. Pharmacol. Exp. Ther. 324, 725-731.
16. Hascup E. R., af B. S., Hascup K. N., Pomerleau F., Huettl P., Stromberg I., et al. (2009) Histological studies of the effects of chronic implantation of ceramic-based microelectrode arrays and microdialysis probes in rat prefrontal cortex. Brain Res. 1291, 12-20.
17. Hascup E. R., Hascup K. N., Stephens M., Pomerleau F., Huettl P., Gratton A., et al. (2010) Rapid microelectrode measurements and the origin and regulation of extracellular glutamate in rat prefrontal cortex. J. Neurochem. 115, 1608-1620.
18. Hascup K. N., Hascup E. R., Stephens M. L., Glaser P. E., Yoshitake T., and, Mathe A. A,., et al. (2011). Resting glutamate levels and rapid glutamate transients in the prefrontal cortex of the flinders sensitive line rat: a genetic rodent model of depression. Neuropsychopharmacology 36, 1769-1777.
19. Helton D. R., Tizzano J. P., Monn J. A., Schoepp D. D., and, Kallman M. J., (1998) Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J. Pharmacol. Exp. Ther. 284, 651-660.
20. Hu E., Chua P. C., Tehrani L., Nagasawa J. Y, Pinkerton A. B., Rowe B. A., et al. (2004) Pyrimidine methyl anilines: selective potentiators for the metabotropic glutamate 2 receptor. Bioorg. Med. Chem. Lett. 14, 5071-5074.
21. Johnson M. P., Baez M., Jagdmann Jr G. E., Britton T. C., Large T. H., Callagaro D. O., et al. (2003) Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2- trifluoroethylsulfonyl)pyrid-3- ylmethylamine. J. Med. Chem. 46, 3189-3192.
22. Johnson M. P., Barda D., Britton T. C., Emkey R., Hornback W. J., Jagdmann G. E., et al. (2005) Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Psychopharmacology 179, 271-283.
23. Linden A. M., Greene S. J., Bergeron M., and, Schoepp D. D., (2004) Anxiolytic activity of the MGLU2/3 receptor agonist LY354740 on the elevated plus maze is associated with the suppression of stress-induced c-Fos in the hippocampus and increases in c-Fos induction in several other stress-sensitive brain regions. Neuropsychopharmacology 29, 502-513.
24. Marek G. J., Wright R. A., Schoepp D. D., Monn J. A., and, Aghajanian G. K., (2000) Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. J. Pharmacol. Exp. Ther. 292, 76-87.
25. Martin E. I., Ressler K. J., Binder E., and, Nemeroff C. B., (2009) The neurobiology of anxiety disorders: brain imaging, genetics, and psychoneuroendocrinology. Psychiatr. Clin. North Am. 32, 549-575.
26. McElligott Z. A., and, Winder D. G., (2009) Modulation of glutamatergic synaptic transmission in the bed nucleus of the stria terminalis. Prog. Neuropsychopharmacol. Biol. Psychiatry 33, 1329-1335.
27. Millan M. J., (2004) The role of monoamines in the actions of established and "novel" antidepressant agents: a critical review. Eur. J. Pharmacol. 500, 371-384.
28. Monn J. A., Valli M. J., Massey S. M., Wright R. A., Salhoff C. R., Johnson B. G., et al. (1997) Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J. Med. Chem. 40, 528-537.
29. Monn J. A., Valli M. J., Massey S. M., Hansen M. M., Kress T. J., Wepsiec J. P., et al. (1999) Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors. J. Med. Chem. 42, 1027-1040.
30. Nickell J., Pomerleau F., Allen J., and, Gerhardt G. A., (2005) Age-related changes in the dynamics of potassium-evoked L-glutamate release in the striatum of Fischer 344 rats. J. Neural Transm. 112, 87-96.
31. Nikiforuk A., Popik P., Drescher K. U., et al. (2010) Effects of a positive allosteric modulator of group II metabotropic glutamate receptors, LY487379, on cognitive flexibility and impulsive-like responding in rats. J. Pharmacol. Exp. Ther. 335 (3), 665-673.
32. Olive M. F., (2009) Metabotropic glutamate receptor ligands as potential therapeutics for addiction. Curr. Drug Abuse Rev. 2, 83-989.
33. Pasquini M., and, Berardelli I., (2009) Anxiety levels and related pharmacological drug treatment: a memorandum for the third millennium. Ann. Ist. Super. Sanita. 45, 193-204.
34. Paxinos G., and, Watson C., (2007) The rat brain: stereotaxic coordinates. Academic Press, New York.
35. Pratt J. A., (1992) The neuroanatomical basis of anxiety. Pharmacol. Ther. 55, 149-181.
36. Riaza Bermudo-Soriano C., Perez-Rodriguez M. M., Vaquero-Lorenzo C., and, Baca-Garcia E,. (2012). New perspectives in glutamate and anxiety. Pharmacol. Biochem. Behav. 100, 752-774.
37. Rowe B. A., Schaffhauser H., Morales S., Lubbers L. S., Bonnefous C., Kamenecka T. M., et al. (2008) Transposition of three amino acids transforms the human metabotropic glutamate receptor (mGluR)-3-positive allosteric modulation site to mGluR2, and additional characterization of the mGluR2-positive allosteric modulation site. J. Pharmacol. Exp. Ther. 326, 240-251.
38. Rutherford E. C., Pomerleau F., Huettl P., Stromberg I., and, Gerhardt G. A., (2007) Chronic second-by-second measures of L-glutamate in the central nervous system of freely moving rats. J. Neurochem. 102, 712-722.
39. Schatzberg A. F., (2002) Pharmacological principles of antidepressant efficacy. Hum. Psychopharmacol. 17, S17-S22.
40. Schoepp D. D., Monn J. A., Marek G. J., Aghajanian G. K., and, Moghaddam B., (1999) LY354740: a systemically active mGlu2/3 receptor agonist. CNS Drug Rev. 5, 1-12.
41. Schoepp D. D., Wright R. A., Levine L. R., Gaydos B., and, Potter W. Z., (2003) LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress 6, 189-197.
42. Stevenson C. W., Sullivan R. M., and, Gratton A., (2003) Effects of basolateral amygdala dopamine depletion on the nucleus accumbens and medial prefrontal cortical dopamine responses to stress. Neuroscience 116, 285-293.
43. Sullivan R. M., and, Gratton A., (1999) Lateralized effects of medial prefrontal cortex lesions on neuroendocrine and autonomic stress responses in rats. J. Neurosci. 19, 2834-2840.
44. Sutherland J. E., Burian L. C., Covault J., and, Conti L. H., (2010) The effect of restraint stress on prepulse inhibition and on corticotropin-releasing factor (CRF) and CRF receptor gene expression in Wistar-Kyoto and Brown Norway rats. Pharmacol. Biochem. Behav. 97, 227-238.
45. Swanson C. J., Bures M., Johnson M. P., Linden A. M., Monn J. A., and, Schoepp D. D., (2005) Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat. Rev. Drug Discov. 4, 131-144.
46. Weinberg M. S., Girotti M., and, Spencer R. L., (2007) Restraint-induced fra-2 and c-fos expression in the rat forebrain: relationship to stress duration. Neuroscience 150, 478-486.
47. Witkin J. M., Marek G. J., Johnson B. G., and, Schoepp D. D., (2007) Metabotropic glutamate receptors in the control of mood disorders. CNS Neurol Disord. Drug Targets 6, 87-100.
48. Zhang L., Brodney M. A., Candler J., Doran A. C., Duplantier A. J., Efremov I. V., et al. (2011) 1-[(1-methyl-1H-imidazol-2-yl)methyl]-4- phenylpiperidines as mGluR2 positive allosteric modulators for the treatment of psychosis. J. Med. Chem. 54, 1724-1739.